VERY-RARE CANCERNasal Cavity CancerWHO 5th Edition Classification

Esthesioneuroblastoma

Very Rare Malignancy (1–5 cases per 1,000,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

Also called olfactory neuroblastoma, this tumour arises from the olfactory neuroepithelium high in the nasal cavity, at the roof of the nose beneath the skull base. Because its early symptoms mimic ordinary sinus disease, it is often diagnosed only after it has eroded upward toward the brain or into the orbit.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Unilateral nasal obstruction with anosmia - image the skull base
Who It Affects

Adults, bimodal peaks in the 20s and 50s-60s

Annual Incidence

Approximately 0.4 per million per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

One-sided nasal blockage that does not resolve
Recurrent nosebleeds from the same side
Loss of the sense of smell
Eye symptoms - proptosis, double vision, tearing - with orbital extension
Headache and, in advanced disease, altered mental state

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

No single defining lesionIDH2 R172 in a subsetSomatostatin receptor 2 expression

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Endoscopic or open craniofacial resection with skull-base reconstruction

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Postoperative radiotherapy - standard for all but the earliest tumours

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Neoadjuvant or adjuvant chemotherapy for advanced Kadish C/D disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Neck dissection or elective neck irradiation for nodal disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Long-term surveillance imaging - late recurrence is well described

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Comparatively favourable for a skull-base malignancy. Five-year survival is around 70-80% overall, driven mainly by Kadish stage and Hyams histological grade; nodal involvement roughly halves survival.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Molecular subtyping is redefining risk groups, and somatostatin-receptor imaging and peptide receptor radionuclide therapy are being explored in receptor-positive tumours.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Esthesioneuroblastoma

Browse All Oncologists

Dr. Alexander G. Chiu

Head & Neck Surgeon

20+ yrs exp

Mayo Clinic

Phoenix, USA

Head & Neck SurgeryEsthesioneuroblastomaEndoscopic Resection
Vetted DirectoryConsult Specialist

Dr. Ian Loh

ENT Surgeon

15+ yrs exp

SGH

Singapore, Singapore

ENT SurgerySinonasal TumorsMinimally Invasive Surgery
Vetted DirectoryConsult Specialist

Prof. Daniele Marchioni

ENT Surgeon

20+ yrs exp

University of Verona

Verona, Italy

ENT SurgeryEsthesioneuroblastomaEndoscopic Endonasal Approach
Vetted DirectoryConsult Specialist

Dr. G. K. Rath

Radiation Oncologist

40+ yrs exp

AIIMS (former)

New Delhi, India

Radiation OncologyEsthesioneuroblastomaIMRT
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

very-rare

Angioimmunoblastic T-cell Lymphoma (AITL)

very-rare

Appendiceal Carcinoma

very-rare

Adenoid Cystic Carcinoma (ACC)

very-rare

Fibrolamellar Hepatocellular Carcinoma (FL-HCC)

Independent Tumor Board Review

Facing a Diagnosis of Esthesioneuroblastoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult